239 related articles for article (PubMed ID: 25680585)
21. Alpha-smooth muscle actin (alpha-SMA) and nestin expression in reactive astrocytes in multiple sclerosis lesions: potential regulatory role of transforming growth factor-beta 1 (TGF-beta1).
Moreels M; Vandenabeele F; Dumont D; Robben J; Lambrichts I
Neuropathol Appl Neurobiol; 2008 Oct; 34(5):532-46. PubMed ID: 18005096
[TBL] [Abstract][Full Text] [Related]
22. [Vitamin D and multiple sclerosis].
Pozuelo-Moyano B; Benito-León J
Rev Neurol; 2013 Feb; 56(4):243-51. PubMed ID: 23400652
[TBL] [Abstract][Full Text] [Related]
23. Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis.
Peelen E; Damoiseaux J; Muris AH; Knippenberg S; Smolders J; Hupperts R; Thewissen M
Mol Immunol; 2015 Feb; 63(2):521-9. PubMed ID: 25458313
[TBL] [Abstract][Full Text] [Related]
24. TGF-beta as a promising option in the treatment of multiple sclerosis.
Mirshafiey A; Mohsenzadegan M
Neuropharmacology; 2009; 56(6-7):929-36. PubMed ID: 19285095
[TBL] [Abstract][Full Text] [Related]
25. Supplementation and therapeutic use of vitamin D in patients with multiple sclerosis: consensus of the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology.
Brum DG; Comini-Frota ER; Vasconcelos CC; Dias-Tosta E
Arq Neuropsiquiatr; 2014 Feb; 72(2):152-6. PubMed ID: 24604370
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma.
Furuzawa-Carballeda J; Ortíz-Ávalos M; Lima G; Jurado-Santa Cruz F; Llorente L
Clin Exp Dermatol; 2012 Aug; 37(6):599-609. PubMed ID: 22731679
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of vitamin D in treating multiple sclerosis-like neuroinflammation depends on developmental stage.
Adzemovic MZ; Zeitelhofer M; Hochmeister S; Gustafsson SA; Jagodic M
Exp Neurol; 2013 Nov; 249():39-48. PubMed ID: 23954214
[TBL] [Abstract][Full Text] [Related]
28. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
29. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers.
Allen AC; Kelly S; Basdeo SA; Kinsella K; Mulready KJ; Mills KH; Tubridy N; Walsh C; Brady JJ; Hutchinson M; Fletcher JM
Mult Scler; 2012 Dec; 18(12):1797-800. PubMed ID: 22457344
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms related to vitamin D and the therapeutic potential of vitamin D in multiple sclerosis.
Niino M; Miyazaki Y
Can J Physiol Pharmacol; 2015 May; 93(5):319-25. PubMed ID: 25798693
[TBL] [Abstract][Full Text] [Related]
31. Transforming growth factor-beta inhibits interleukin-10 synthesis by human monocytic cells.
Suberville S; Bellocq A; Peguillet I; Lantz O; Stordeur P; Fouqueray B; Baud L
Eur Cytokine Netw; 2001 Mar; 12(1):141-6. PubMed ID: 11282558
[TBL] [Abstract][Full Text] [Related]
32. Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis.
Weinstock-Guttman B; Zivadinov R; Ramanathan M
J Neurol Sci; 2011 Dec; 311(1-2):86-91. PubMed ID: 21849177
[TBL] [Abstract][Full Text] [Related]
33. [Serum levels of interleukin-6 and interleukin-10 in patients with multiple sclerosis during intravenous immunoglobulin infusion].
Kazibutowska Z; Motta E; Huć M; Strzała-Orzeł M; Woźnik G
Wiad Lek; 2006; 59(9-10):626-9. PubMed ID: 17338118
[TBL] [Abstract][Full Text] [Related]
34. Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis.
Chaudhuri A
Med Hypotheses; 2005; 64(3):608-18. PubMed ID: 15617877
[TBL] [Abstract][Full Text] [Related]
35. Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?
Breuer J; Loser K; Mykicki N; Wiendl H; Schwab N
J Neuroimmunol; 2019 Apr; 329():1-8. PubMed ID: 29793727
[TBL] [Abstract][Full Text] [Related]
36. [Impact of vitamin D in neurological diseases and neurorehabilitation: from dementia to multiple sclerosis. Part I: the role of vitamin D in the prevention and treatment of multiple sclerosis].
Speer G
Ideggyogy Sz; 2013 Sep; 66(9-10):293-303. PubMed ID: 24358684
[TBL] [Abstract][Full Text] [Related]
37. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D and multiple sclerosis: a critical review and recommendations on treatment.
Faridar A; Eskandari G; Sahraian MA; Minagar A; Azimi A
Acta Neurol Belg; 2012 Dec; 112(4):327-33. PubMed ID: 22767049
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor-beta1 affects interleukin-10 production in the bone marrow of patients with chronic idiopathic neutropenia.
Pyrovolaki K; Mavroudi I; Papadantonakis N; Velegraki M; Ximeri M; Kalpadakis C; Gvazava G; Klaus M; Eliopoulos GD; Papadaki HA
Eur J Haematol; 2007 Dec; 79(6):531-8. PubMed ID: 17961177
[TBL] [Abstract][Full Text] [Related]
40. Transforming growth factor-beta1 gene expression and cyclosporine A-induced gingival overgrowth: a pilot study.
Radwan-Oczko M; Boratyńska M; Zietek M; Dobosz T
J Clin Periodontol; 2008 May; 35(5):371-8. PubMed ID: 18355347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
